Today we announced a number of business updates, including the appointment of Dr. Patrik Foerch as Chief Scientific Officer and President of Nxera Pharma UK. Dr. Foerch brings extensive R&D leadership and a strong track record in applying AI to drug discovery and development. His appointment will further strengthen our global R&D capabilities and advance our mission to deliver next-generation therapies powered by our NxWave™ platform. Read more in our press release here: https://lnkd.in/ec9cyGmK
Nxera Pharma
バイオテクノロジー研究
Tokyo、Tokyo13,584人のフォロワー
Nxera Pharma is a technology-powered biopharma company.
概要
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWave” platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
- ウェブサイト
-
https://www.nxera.life
Nxera Pharmaの外部リンク
- 業種
- バイオテクノロジー研究
- 会社規模
- 社員 201-500名
- 本社
- Tokyo、Tokyo
- 種類
- 上場企業
- 創立
- 1990
- 専門分野
- GPCR、Drug Discovery、Pre-Clinical、Immunology、Gastroenterology、Neurology、Inflammatory、Chemistry、Molecular Pharmacology、Development、Computational Chemistry、Structure-Based Drug Design platform capabilities、Novel Medicines
場所
Nxera Pharmaの社員
アップデート
-
We’ve received a manufacturing approval partial amendment regarding the addition of a manufacturing site in Asia for QUVIVIQ®. This second manufacturing facility has been added to ensure supply for patients with insomnia in Japan and for future demand across the Asia-Pacific region. Read more here: https://lnkd.in/eH97KPJC
-
-
Today we released our Q3 2025 financial results. We made strong progress in advancing our plans for obesity and metabolic diseases with our newly launched proprietary pipeline, led by our differentiated oral GLP-1 agonist and including multiple complementary GPCR-targeted programs. Advancements in our partnered programs and with a robust pipeline of data and milestones ahead, we are well positioned to close the year with strong momentum. Read the full announcement here: https://lnkd.in/e97kwwjp
-
-
Our partner Cancer Research UK presented data from the successfully completed Phase 1 part of the ongoing Phase 1/2a clinical trial of our immunotherapy drug HTL0039732 at the European Society for Medical Oncology Congress (ESMO) 2025. HTL’732 was found to be well-tolerated, confirmed target engagement and demonstrated encouraging early efficacy in two distinct tumor types when administered in combination with atezolizumab. Read more here: https://lnkd.in/eUYCKDZM
-
-
We’ve reached a second important R&D milestone in our multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera. Reaching this second milestone highlights the continued productivity of our collaboration with AbbVie, and reflects the remarkable work of our teams in applying our NxWave™ platform to discover and advance novel molecules that modulate neurological disease targets. Read more here: https://lnkd.in/eFPBNVRx
-
-
🚀 Take a look inside our state-of-the-art R&D facilities in our new Lab Tour! The video takes you through each stage of our NxWave platform to show you how our scientists develop breakthrough novel medicines that have the potential to change patients' lives. #DrugDiscovery #GPCR #Biopharma #GrantaPark
-
We're proud to share that Graeme Scarfe, Director of DMPK at Nxera, was honoured with a DMDG Fellowship at the Annual DMDG Conference earlier this month. This fellowship recognizes Graeme's outstanding contributions and long-standing commitment to the DMDG. Congratulations, Graeme!
Congratulations to Graeme Scarfe for being awarded a DMDG Fellowship. Graeme is an exemplary DMDG member, ex-Committee Member and Chair and current Fundamentals Course Leader, first being introduced to the DMDG in 1989! His commitment to the DMDG cause has been outstanding and it was a great honour to be given an insight into his career and involvement in developing the DMDG over these many years. Thank you Graeme! 👏 ⭐ 🎉
-
-
-
-
-
+1
-
-
The first patient has been dosed in a Phase 2a trial of HTL0039732, our novel oral EP4 antagonist, for advanced solid tumors, sponsored and managed by Cancer Research UK's Centre for Drug Development. The initiation of the Phase 2a trial marks a significant step forward in our efforts to bring this promising drug to patients with difficult-to-treat cancers. Read more here: https://lnkd.in/eB2mrprS
-
-
Our COO and President of NPJ, Toshihiro Maeda, presented at the Reuters Pharma Japan Conference in Tokyo last week. Toshi’s presentation, titled: “Breaking the barrier: Nxera Pharma’s challenge in building a global biopharma from Japan”, looked at the key barriers that have held Japanese biopharma companies back in comparison to the West, and explained how our strategy at Nxera directly tackles these. https://lnkd.in/dZHZZzW4 #REPharmaJP Reuters Events Pharma
-
-
We’re sponsoring the BioCentury Inc. Grand Rounds Europe event taking place in Cambridge on 17-19 September. Our CSO and President of Nxera Pharma UK, Matt Barnes, will be taking part in a panel titled “Small compounds, big potential: The next era of chemistry”. We look forward to connecting with many of you there!
-